Ovarian cancer can be cured in up to 90% of cases if diagnosed early. CA125, the most studied ovarian cancer biomarker, exhibits poor sensitivity for detecting early disease stages and low specificity to malignancy. RECAF, the alpha-fetoprotein receptor, is a wide-spectrum oncofetal antigen with clinical potential for cancer diagnosis, screening, and monitoring. This study evaluated the performance of RECAF as a diagnostic tool and the sensitivity of a combination of RECAF and CA125 to detect early stages of ovarian cancer at a cutoff resulting in 100% specificity among healthy women. This retrospective case–control study was designed to measure the serum levels of RECAF and CA125 in normal individuals (n = 106) and cancer patients stages I/II (RECAF, n = 32; CA125, n = 35) and III/IV (RECAF, n = 49; CA125, n = 51). A competitive chemiluminescence assay was developed to measure the circulating RECAF. To eliminate any false positives, we classified as positive any patient with a RECAF or a CA125 value higher than their respective 100% specificity cutoff. We have shown that RECAF discriminated cancer and healthy donors better than CA125, particularly in the early stages (AUCRECAF = 0.96 and AUCCA125 = 0.805). CA125 sensitivity was lower in the early stages than in the advance stages; RECAF sensitivity was high at all stages. A combination of CA125 and RECAF detected three out of four early-stage patients, with no false positives. In conclusion, the combination of RECAF and CA125 serum values provides the specificity and the sensitivity necessary to screen for ovarian cancer and in particular, to detect early stages of the disease.
Moro R, Tcherkassova J, Song E, Shen G, Moro R, Schmid R, Hu X, Kummer A, Chen C (2005) A new broad-spectrum cancer marker. In-Vitro Diagnostic Technology.
Trojan J, Uriel J. Immunocytochemical localization of alpha-fetoprotein in the developing rat brain. Oncodev Biol Med. 1980;1:107–11. PubMed
Uriel J, Villacampa MJ, Moro R, Naval J, Failly-Crepin C. Uptake of radiolabeled alpha-fetoprotein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. Cancer Res. 1984;44:5314–9. PubMed
Kanevsky V, Pozdnyakova LP, Aksenova OA, Severin SE, Katukov V, Severin ES. Isolation and characterization of AFP-binding proteins from tumor and fetal human tissues. Biochem Mol Biol Int. 1997;41:1143–51. PubMed
Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal. 2010;10:1919–31. PubMed
Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010;2010:149362. PubMed
Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12. PubMed
Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev. 2000;9:1107–11. PubMed
Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast Jr RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14–8. PubMed
Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. He4 and mesothelin: Novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2011;11:111–6.
- Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
- Springer Netherlands
Neu im Fachgebiet Onkologie
Mail Icon II